LENZ Therapeutics Reports Third Quarter 2024 Financial Results
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash, cash equivalents and marketable securities of $217.2 million as of September 30, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 8:00 a.m. ET SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today reported financial results and operational highlights for the third quarter ended Sep
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024GlobeNewswire
LENZ
Earnings
- 11/6/24 - Beat
LENZ
Sec Filings
- 12/17/24 - Form 4
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- LENZ's page on the SEC website